Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Suzhou's CStone Pharma Starts Phase I Trial of PD-L1 Candidate

publication date: Oct 20, 2017

CStone Pharma of Suzhou has dosed the first patient in a Phase I trial of its anti-PD-L1 monoclonal antibody. The company claims CS1001 is China's first fully human and full-length PD-L1 candidate. Founded in late 2014, CStone has become a clinical-stage pharma in under two years, a remarkably short time. In July 2015, CStone announced a $150 million Series A funding from three China VCs, one of which is WuXi Healthcare Ventures. WuXi AppTec has China rights to the Ligand OMT transgenic animal platform that was used to generate CS1001. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital